on IFabric Corp (CVE:IFA)
IFabric's Clinical Trial Validates Infection Control with Treated Scrubs
IFabric Corp announced that the Journal of Hospital Infection has published the results of a clinical trial demonstrating the effectiveness of their antimicrobial-treated fabric scrubs. Conducted by Intelligent Fabric Technologies at Saddleback Medical Center, this study showcased significant reductions in bacterial loads on scrubs treated with PROTX2® and ecoPEL™ technology.
The trial emphasized the superiority of these treated scrubs over untreated ones, suggesting a substantial impact on infection control in healthcare settings. Giancarlo Beevis, CEO of IFTNA, highlighted the potential of PROTX2® as a pivotal solution in reducing healthcare-associated infections, asserting its unmatched industry performance.
The technology is registered with the EPA and available in the United States, promising economic benefits for healthcare facilities by lowering infection rates and associated costs.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IFabric Corp news